BioStock: Saniona’s CMO on the new clinical trial with SAN711
Saniona has generated promising preclinical data with SAN711 in multiple models of pain and rare neuropathic disorders. BioStock reached out to Rudolf Baumgartner, MD, Chief Medical Officer and Head of Clinical Development at Saniona, to learn more about the newly-initiated phase I safety study in healthy volunteers.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital.https://www.biostock.se